for veteran patients in stages 1-3.

  • KidneyIntelX is the only bioprognostic methodology and the only option for early-stage risk assessment in veteran patients with type 2 diabetes and with chronic kidney disease stages 1-3.
  • Demonstrated to be a 3X better predictor of risk vs traditional kidney function measures (eGFR and UACR)

References:
1. Data from Validation Study in Subgroup with UACR available Chan L, et al. Diabetologia 2021
2. Data from CANVAS analyses; Lam D, et al. Am J Nephrology 2021

KidneyIntelX begins at the
right starting point.

Only by starting at the earliest stages of diagnosed diabetic kidney disease – and by leveraging the only test demonstrated to identify those select adult veteran patients with type 2 diabetes and chronic kidney disease who are at higher to lower risk for rapid progressive decline in kidney function – will clinicians and veterans reap the greatest benefits from the rest of the treatment plan.